NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
Clinical Trials
6 trialsNCT03035032 2024-11-26
A Study of ELIGARDĀ® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT00220194 2016-10-14
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
San Bernardino Urological Associates Medical Group Inc
Phase 4 Completed
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed
NCT00805935 2012-01-27
MenopurĀ® Versus FollistimĀ® in Polycystic Ovarian Syndrome (PCOS)
Ferring Pharmaceuticals
Phase 4 Completed